Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
The plant is yet to start commercial operations
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Subscribe To Our Newsletter & Stay Updated
